FDA accepts ELIQUIS® (apixaban) New Drug Application for review
29 November 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. FDA has accepted for review a NDA for ELIQUIS® (apixaban)...
List view / Grid view
News
Sanofi confirms its decades-long commitment to the fight against Malaria
29 November 2011 | By Sanofi
Sanofi organizes the 10th Edition of the Pan-African Conference against Malaria with representatives of 34 African Countries...
KOMBOGLYZE™ receives marketing authorisation in the European Union for adult patients with Type 2 diabetes
29 November 2011 | By AstraZeneca
The European Commission has granted marketing authorisation for KOMBOGLYZE™...
ONGLYZA® (saxagliptin) approved for use in Europe as combination therapy with insulin in adults with type 2 diabetes
28 November 2011 | By Bristol-Myers Squibb Company
The European Commission has approved ONGLYZA® (saxagliptin)...
AstraZeneca commits an additional $100 million to venture capital arm MedImmune Ventures
28 November 2011 | By AstraZeneca
MedImmune Ventures closes investment in Australian company, NeuProtect Pty Ltd...
EDURANT® (rilpivirine) approved in Europe
28 November 2011 | By Daniel J Edelman Ltd
The European Commission has granted marketing authorisation for EDURANT® (rilpivirine)...
Cambridge-Elan Centre for Research Innovation and Drug Discovery launched
28 November 2011 | By F T I Consulting
World’s leading researchers work together on therapeutic advances in neuroscience...
Novartis gains European Commission approval for Rasitrio®
28 November 2011 | By Novartis
Rasitrio®, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide in a single pill has received approval...
Abbott expands agreement with GSK to include development of a companion diagnostic test for an additional investigational cancer immunotherapy antigen
28 November 2011 | By Abbott
Abbott announced that it will expand its existing agreement with GSK...
Gilead receives European marketing authorization for Eviplera®
28 November 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Eviplera®...
New Syrris Asia catalogue highlights the benefits of flow chemistry
23 November 2011 | By kdm communications limited
Syrris is pleased to announce the release of its new Asia flow chemistry reactors catalogue...
A drug for Type 1 diabetes meets primary and secondary goals of Phase III clinical trials
23 November 2011 | By Weizmann UK
The clinical trial was random, regulated, double-blinded and broad-based...
Pfizer to acquire Excaliard Pharmaceuticals
22 November 2011 | By Pfizer
Lead program includes novel investigational compound for prevention/treatment of skin scarring...
NDA for aripiprazole depot formulation for maintenance treatment of adult patients with schizophrenia accepted
22 November 2011 | By H. Lundbeck A/S (Lundbeck)
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today that the US Food and Drug Administration (FDA) has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit…
Sunrise™ in Mongolia
22 November 2011 | By kdm communications limited
Donation of a Tecan Sunrise™ microplate reader to Mongolian medical researchers, assisting their studies of vitamin D levels in the general population...
